This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Finkelstein, J. S. Articles by Neer, R. M. Search for Related Content PubMed PubMed Citation Articles by Finkelstein, J. S. Articles by Neer, R. M. Related Collections Calcium and Bone Metabolism Male Endocrinology

Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men

Endocrine Unit, Department of Medicine (J.S.F., B.Z.L., S.-A.M.B., J.J.W., K.G., A.V.d.l.P., R.M.N.) and Biostatistics Center (H.L.), Massachusetts General Hospital, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Joel S. Finkelstein, M.D., Endocrine Unit, Bulfinch 327, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114. E-mail: jfinkelstein{at}partners.org.

Context: We have previously demonstrated that alendronate reduces the ability of teriparatide to increase bone mineral density (BMD) in osteoporotic men. The underlying basis for this observation is poorly understood.

Objective: The primary aim of this study was to determine whether teriparatide increases osteoblast activity when the ability of teriparatide to increase osteoclast activity is suppressed by alendronate.

Design: This was a nonblinded, randomized, controlled trial.

Setting: The study was conducted at the General Clinical Research Center of a teaching hospital.

Patients: We studied 63 men, age 46–85, with low spine and/or hip BMD.

Interventions: Subjects received alendronate 10 mg daily (group 1), teriparatide 37 µg sc daily (group 2), or both (group 3) for 30 months. Teriparatide was begun at month 6.

Main Outcome Measures: The primary endpoint was the change in serum N-telopeptide, osteocalcin, and amino-terminal propeptide of type 1 procollagen.

Results: In men receiving teriparatide monotherapy (group 2), levels of all bone turnover markers increased markedly during the first 6 months of teriparatide administration and then declined toward baseline during the next 18 months. In men who received combination therapy (group 3), bone turnover marker levels declined in the first 6 months (while receiving alendronate alone) and then returned to baseline levels (N-telopeptide) or above (osteocalcin and amino-terminal propeptide of type 1 procollagen) after teriparatide was added. Changes in each marker were significantly different between groups 1 and 2 (all P values < 0.001), groups 1 and 3 (all P values < 0.001), and groups 2 and 3 (all P values < 0.03).

Conclusions: As with BMD, alendronate impairs the action of teriparatide to increase bone turnover in men.

This article has been cited by other articles:

				J. S. Finkelstein, J. J. Wyland, B. Z. Leder, S.-A. M. Burnett-Bowie, H. Lee, H. Juppner, and R. M. Neer Effects of Teriparatide Retreatment in Osteoporotic Men and Women J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2495 - 2501. [Abstract] [Full Text] [PDF]

				A.E. Kearns and D.F. Kallmes Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1816 - 1822. [Abstract] [Full Text] [PDF]

				P. D. Miller, P. D. Delmas, R. Lindsay, N. B. Watts, M. Luckey, J. Adachi, K. Saag, S. L. Greenspan, E. Seeman, S. Boonen, et al. Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3785 - 3793. [Abstract] [Full Text] [PDF]

				M. T. Drake, B. L. Clarke, and S. Khosla Bisphosphonates: Mechanism of Action and Role in Clinical Practice Mayo Clin. Proc., September 1, 2008; 83(9): 1032 - 1045. [Abstract] [Full Text] [PDF]

				S. Khosla, S. Amin, and E. Orwoll Osteoporosis in Men Endocr. Rev., June 1, 2008; 29(4): 441 - 464. [Abstract] [Full Text] [PDF]

				L. Gehrig, J. Lane, and M. I. O'Connor Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374. [Full Text] [PDF]

				P. G Clay, L. E Voss, C. Williams, and E. C Daume Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons Ann. Pharmacother., May 1, 2008; 42(5): 670 - 679. [Abstract] [Full Text] [PDF]

				J. Stroup, M. P. Kane, and A. M. Abu-Baker Teriparatide in the treatment of osteoporosis Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 532 - 539. [Abstract] [Full Text] [PDF]

				S. Boonen, F. Marin, B. Obermayer-Pietsch, M. E. Simoes, C. Barker, E. V. Glass, P. Hadji, G. Lyritis, H. Oertel, T. Nickelsen, et al. Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 852 - 860. [Abstract] [Full Text] [PDF]

				S. A.J. Lloyd, N. D. Travis, T. Lu, and T. A. Bateman Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse J Appl Physiol, March 1, 2008; 104(3): 729 - 738. [Abstract] [Full Text] [PDF]

				S. Johnston, S. Andrews, V. Shen, F. Cosman, R. Lindsay, D. W. Dempster, and A. Iida-Klein The Effects of Combination of Alendronate and Human Parathyroid Hormone(1 34) on Bone Strength Are Synergistic in the Lumbar Vertebra and Additive in the Femur of C57BL/6J Mice Endocrinology, September 1, 2007; 148(9): 4466 - 4474. [Abstract] [Full Text] [PDF]

				D. Shoback Update in Osteoporosis and Metabolic Bone Disorders J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 747 - 753. [Abstract] [Full Text] [PDF]